3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Phase 2/3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
4
Osteoporosis
3
Prostatic Neoplasms
2
Pain
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm Metastasis
1
Myocardial Ischemia
1
Multiple Myeloma
1
Lymphoma
1
Lung Neoplasms
1
Leukemia
1
Heart Diseases
1
Disease Progression
1
Coronary Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Cardiovascular Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Bone Diseases, Metabolic
1
Bone Diseases
1
Interventions
Fluorouracil
131
Leucovorin
127
Oxaliplatin
93
Bevacizumab
86
Irinotecan
74
Capecitabine
63
Cetuximab
47
Folfox protocol
32
Panitumumab
18
regorafenib
16
trifluridine tipiracil drug combination
15
Drug Therapy
14
Chemotherapy, Adjuvant
13
IFL protocol
10
Floxuridine
10
Radiotherapy
9
Tegafur
7
Neoadjuvant Therapy
7
Levoleucovorin
7
Laparoscopy
7
Aspirin
7
pembrolizumab
6
Trifluridine
6
Celecoxib
6
atezolizumab
5
XELOX
5
Mitomycin
5
Colonoscopy
5
tipiracil
4
sintilimab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Colorectal Neoplasms
×
Calcium
×
Clear all
NCT01087658
2013-06-21
GLUTOX
Sanofi
Phase 3
Completed
200 enrolled